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Introduction 
Skin and soft tissue infections (SSTI) are amongst the most common infections encountered in clinical 
practice. Although the majority of infections do not result in skin or tissue necrosis, those that do are 
associated with a high mortality rate. In addition, due to the surreptitious presentation of the disease 
clinical recognition is often delayed resulting in rapid and overwhelming morbidity.  
Necrotising skin and soft tissue infections (NSSTI) are a spectrum of conditions and their presentation 
can vary depending on host and microbial factors. NSSTI can spread in the superficial skin layers 
causing a necrotising cellulitis or within deeper skin layers along the fascial planes causing necrotising 
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fasciitis (NF) and can occasionally invade muscles causing a necrotising pyomyositis. A variety of 
microorganisms may be responsible and common pathogens under certain conditions and in certain 
hosts may become aggressive and invasive resulting in skin death despite adequate treatment.  
A number of ‗hot topics‘ on NSSTI were selected and reviewed by members of the Skin, Soft Tissue 
and Bone Infections Working Group of the International Society of Antimicrobial Chemotherapy 
(ISAC). This group includes international scientists, microbiology and infectious diseases clinicians 
and academics, aiming to advance the education and the science of infection management. The 
following represents an in-depth review of the current literature providing a summary of the various 
NSSTIs and expert opinions and insights from the authors‘ own experience, highlighting areas for 
future study and research.   
 
1. Necrotising fasciitis: an overview 
Necrotising fasciitis (NF) is a severe, uncommon, potentially life-threatening infection if adequate 
debridement is not administered promptly [1]. Higher rates of disease are seen in men, and middle-
aged and elderly patients, although all age groups can be affected. Rates of 0.4/ 100,000 people per 
year in the USA and 1/100,000 in other countries have been reported however this may underestimate 
the true incidence of the disease.  
Conditions associated with NF include diabetes mellitus, renal insufficiency, arterial occlusive disease, 
intravenous drug abuse, body mass index > 30 kg/m², age > 65 years, liver disease, 
immunosuppression, recent surgery, and traumatic wounds or incision of the skin including minor 
lesions such as insect bites and injections sites [2-4]. NF has been classified into four types depending 
on microbiological findings: type I is of polymicrobial aetiology, including aerobic and anaerobic 
organisms; type II is caused by group A streptococci (GAS), either alone or in association with 
staphylococci; type III is represented by monomicrobial infections attributable to Clostridium species 
or Gram-negative bacteria; type IV is of fungal aetiology [1,5]. However, failure to identify an 
organism should never override the clinical diagnosis of NF.  
Early diagnosis of NF is crucial, but can be challenging (Figure 1). The triad of swelling, erythema, 
and disproportionately severe pain should raise the suspicion of NF and the presence of blisters, bullae 
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and skin crepitus is strongly suggestive. The Laboratory Risk Indicator for NF (LRINEC) is a scoring 
system encompassing six routinely performed laboratory tests used in conjunction with clinical signs, 
and has been used to distinguish early NF from the other severe SSTI. The laboratory tests include C-
reactive protein (CRP), mg/L ( < 150 scores  0,  >150  scores  4), total white cell count (WBC), 
cells/mm (<15 scores 0, > 25 scores 2),  haemoglobin, (Hb) g/dL(>13.5 scores 0, < 11 scores 
2), sodium, mmol/L (≥ 135 scores 0,  < 135 scores 2), creatinine, mg/dL  (≤ 1.6  scores 0, >1.6 scores 
2) and glucose, mg/dL (≤ 180 scores 0, >180 scores 1)] [6-9]. In one study the cut-off point of 
LRINEC scoring for predicting septic shock was 5 points (sensitivity 82% and specificity 38%) 
whereas the cut-off point for predicting mortality was 8 points (sensitivity 81% and specificity 36%). 
[9]. However, the usefulness of this score is still debated [6, 10] and although it may have a place in 
potentially including NF in a patient‘s clinical diagnosis, it should not be used to exclude it.  
Although imaging can provide useful information, it lacks specificity and should not delay prompt 
surgical management when NF is suspected. The gold standard for diagnosis of NF remains surgical 
exploration [1, 5, 11, 12]. Early radical surgical debridement with removal of all necrotic and infected 
tissues is imperative in the treatment of NF and amputation of the affected limb may be necessary to 
achieve source control. Delayed first debridement is often associated with poor outcomes, while 
operating early tends to result in shorter hospital and Intensive Care Unit (ICU) lengths of stay [13, 
14]. Empiric treatment with broad-spectrum antibiotics, guided by local epidemiology and resistance 
patterns, should be administrated early (Table 1), followed by targeted therapy if a pathogen is 
identified.  The duration of optimum treatment is not defined, but should be continued until 
debridement is optimised and no further surgery is needed and there has been a clinical improvement.  
The role of intravenous immunoglobulin G (IVIG) therapy is discussed below. There is still no clear 
evidence to support the role of hyperbaric oxygen (HBO) as an adjunctive treatment in NF 
management but it may contribute to decreasing mortality and limiting the extent of debridement 
necessary [15]. Vacuum-assisted closure (VAC) devices allow the continuous cleansing of the wound 
and are widely used to improve and accelerate wound healing [1, 5, 11,12, 16]. Reactive Oxygen gels 
have been used topically to suppress the bacterial load in tissue and support healing and may be used 
as an adjuvant to debridement and antibiotic therapy [17].  
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2. Group A Streptococcal necrotising fasciitis 
GAS is one of the most common organisms isolated in cases of NF [18]. Certain strains are more 
pathogenic with the emm1 strain being the major lineage associated with invasive disease in Europe 
and the USA. Sequencing of an emm1 strain causing genital tract soft tissue necrosis, haemorrhagic 
pneumonia and streptococcal toxic shock has confirmed that spontaneous mutations may make strains 
of GAS become super-pathogens [19]. In one outbreak of GAS a mutation in the sic allele was 
associated with the outbreak isolates but was never identified again in isolates of GAS from the same 
region, suggesting that super-pathogens of this sort cause catastrophic infection in small numbers of 
patients, but do not possess the characteristics to persist in the host population [19]. Emm1 GAS is 
equipped with a range of virulence factors that allow it to cause a wide spectrum of disease [20], from 
asymptomatic colonisation, through to tonsillitis, cellulitis, NF, haemorrhagic pneumonia and 
bacteraemic toxic shock as well as the ability to cause outbreaks [21]. Despite the above, a wide 
variety of emm types of GAS can cause NF, and emm-1 may cause non-invasive infection, hence the 
importance of emm type remains unclear. 
The diagnosis depends on clinical suspicion [22] (Figure 1). The presentation of GAS NF is illustrated 
by the case of a 49-year old woman (Figure 2a and 2b). Early surgical exploration of the soft tissues 
has little morbidity and may be the only means to reach a definitive diagnosis and expedite treatment. 
The earlier the first exploration and subsequent debridement, the less extensive the resection and 
postoperative morbidity is likely to be [13, 14].  
 
3. Gram negative bacterial necrotising fasciitis 
Although Gram positive organisms are more typically associated with NSSTI, a variety of Gram 
negative organisms may also be responsible depending on local epidemiological and host factors.  
In a retrospective study of 323 consecutive patients with NF in Taiwan, monomicrobial infections 
were detected in 187 cases, 125 by tissue culture and 61 by blood culture; Staphylococcus aureus was 
identified in  33.7% of cases, GAS in 9.6%, Vibrio vulnificus in 21.9%, Aeromonas species in 9.1% 
and Klebsiella pneumoniae in 9.0% [23]. Another Taiwanese study identified 42 patients with 
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cirrhosis and NF, among which monomicrobial infections were detected in 41 patients and were 
mainly caused by Gram negative bacteria (76%) including Vibrio species (36%), Klebsiella species 
(21%), and Aeromonas species (14%). Patients with NF due to Gram negative bacteria were more 
likely to present with septic shock, but had similar in-hospital mortality compared with Gram positive 
NF [24].  
A retrospective case series of 67 patients with V. vulnificus NF from Taiwan showed male 
predominance (n=52), cirrhosis in 23 patients, chronic renal impairment in 17, upper limbs affected in 
50, shock in 8, bacteraemia in 38 and death in 8. Repeated debridement of 4 or more times was needed 
in 39 cases and amputation in 3 [25].  In another retrospective study of 100 patients with V. vulnificus, 
delayed presentation of at least 3 days from disease onset was found to be an independent predictor of 
mortality [26]. Another retrospective study comparing 60 patients with V. vulnificus and 55 with S. 
aureus NF found leukopenia, thrombocytopenia, liver disorders, seawater and seafood exposure, ICU 
admission and a temperature of 38.5
o
C or above to be significantly more common in V. vulnificus, 
while diabetes mellitus, trauma, surgical wound infection and ulcers to be significantly more common 
in S. aureus NF [27]. V. vulnificus should be considered in any patient with known iron overload 
presenting with NF and empiric therapy should provide coverage for this organism. 
In terms of diagnosis, a retrospective study of 70 patients with V. vulnificus with 18 deaths showed 
similar mean LRINEC scores between survivors and those who died, and only 8 had an LRINEC score 
of 6 or more [28]. However, LRINEC scores of 2 or more was shown to have a sensitivity of 71%, 
specificity of 83% and negative predictive value of 85% in a retrospective study of 125 patients with 
V. vulnificus soft tissue infections of which 72 had NF [7].  
A study of 89 patients with V. vulnificus NF showed a fluoroquinolone with or without minocycline, 
and third generation cephalosporins with minocycline were associated with significantly lower case 
fatality rates (14%) compared with third generation cephalosporins alone (61%) [29]. Surgical 
debridement within 12 hours of hospital presentation was shown to be associated with lower mortality 
compared with debridement within 12 to 24 hours or over 24 hours, adjusted for age, duration between 
disease onset and hospital presentation and illness severity, in a retrospective study of 121 patients 
with V. vulnificus NF of which 35 died [30]. The only study outside of Taiwan on V. vulnificus NF 
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with septic shock was undertaken in China and showed less bleeding, lower intraoperative fluid and 
maximum dose of inotropic requirements, and lower mortality in 19 patients who received initial 
incision and drainage under regional anaesthesia followed by debridement over 24 hours later 
compared with 15 who received immediate surgical debridement, with similar baseline characteristics 
and illness severity [31]. 
Table 2 [32-37] summarises salient clinical data from the largest reported case series and literature 
reviews on other Gram negative bacterial NF. The largest cases series was reported for Pseudomonas 
species (n=37), followed by K. pneumoniae (n=17) and Aeromonas species (n=13). Notably, 
Pseudomonas species NF occurred in younger patients (14/37 less than 10 years old) with neutropenia 
(11/37) and frequently involved the perineum (20/37). Likewise Salmonella species NF affected 
younger patients with only 1/6 above 40 years old. Male predominance was observed in most except 
Pseudomonas species (15/37) and Salmonella species (2/6) NF. Diabetes mellitus was the main 
predisposing condition in K. pneumoniae (12/17), and corticosteroid use was reported in 4/6 with 
Salmonella species NF. Cancers were found in patients with Aeromonas species (5/13), Pseudomonas 
species (20/37) and E. coli (3/7) NF. Surgery was performed in the majority of patients in these series 
except Pseudomonas species (16/37) and E. coli (2/7) NF. Mortality was particularly high (>50%) in 
Aeromonas species (9/13) and E. coli (7/7) NF.  
 
4. PVL-positive Staphylococcus aureus related necrotising infections  
Panton-Valentine leukocidin (PVL) is a bicomponent, poreforming cytotoxin that causes leukocyte 
destruction and tissue necrosis produced by both methicillin sensitive and methicillin resistant S. 
aureus (MRSA). Risk factors for PVL related necrotising infections are; compromised skin integrity, 
skin-to-skin contact, including contact sports e.g. wrestling, sharing of contaminated towels and sheets 
and living in crowded accommodation [38]. Necrosis can be focal or more extensive including 
Fournier‘s gangrene, and secondary abscesses are common. Necrosis, abscesses and tissue destruction 
are suggested by local and general inflammatory symptoms [38]. Robust epidemiological evidence in 
the early 2000s had shown a strong association between S. aureus carrying the PVL gene and lethal 
necrotising pneumonia [39]. However, other studies have questioned the role of PVL as a consistent 
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predictor of poorer clinical outcomes [40]. Experimental evidence demonstrating a causal association 
between PVL and necrotising infections is also conflicting particularly in murine models of infection 
[41]. It has been demonstrated in both correlation studies and experimental studies that in the absence 
of PVL other virulence factors can induce the necrotising phenotype of community-acquired (CA-
)MRSA, for example alpha-haemolysin, phenol-soluble modulin peptides and the arginine catabolic 
mobile element.  
Early aggressive surgical debridement is recommended for patients with severe infections associated 
with signs of systemic toxicity where NF is suspected [42]. Currently inhibitors of toxin production 
such as clindamycin, linezolid or rifampicin are recommended for inclusion in antimicrobial treatment 
of necrotising infections related to pvl positive S. aureus. A recent study indicated that treatment with 
tedizolid or linezolid alone yields higher survival rates than vancomycin in a rabbit model of 
necrotising pneumonia while the effect on bacterial counts in the lungs was comparable to vancomycin 
[43]. Combinations of vancomycin with clindamycin or rifampicin and linezolid or clindamycin with 
rifampicin have demonstrated clinical success and are discussed in a position statement from the ISAC 
[44]. A recent RCT of adjunctive clindamycin in non-necrotising cellulitis of the lower limb found no 
benefit, and an excess of diarrhoea in the clindamycin arm. However, lower doses of clindamycin 
were used, and prior usage for coamoxiclav did not account for this side effect [45]. A current 
Australian trial is evaluating the role of adjunctive clindamycin in children and adults with severe S. 
aureus infections, including pyomyositis and pneumonia (ACTR number to follow), but specific trials 
are needed in patients with NSSTI.  
 
 
5. Fungal necrotising skin and soft tissue infections 
 
Fungal NF is rare and most descriptions are limited to case reports. In healthy individuals fungal NF 
can follow soil exposure, motor-vehicle related trauma or burns [46] and can occasionally arise from 
an iatrogenic source after injections or contaminated surgical dressings. In immunocompromised 
patients infection often results from an extrinsic source and progression from a painless papule to 
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necrotising infection may occur surreptitiously or as a fulminant process.  Necrosis has been 
documented in up to 60% of these cases [47]. 
 
 
Fungal NF is usually due to infection by moulds including Aspergillus species, or more typically by 
zygomycete fungi, in particular Apophysomyces species has been primarily associated with infection 
in previously healthy patients following severe trauma potentially contaminated with soil. Jain et al 
reported 18 cases of zygomycotic NF from a single institute in India. Identification was by tissue 
biopsy and fungal culture [48]. Similarly, after a tornado in Missouri in 2011, a cluster of 13 patients 
with severe NSSTI were infected with a new species of Apophysomyces (Apophysomyces 
trapeziformis). The mortality rate was high (38%) despite surgical debridement and antifungal therapy 
including liposomal amphotericin, azoles and echinocandins[49].  
 
 
In immunocompromised patients skin infection may also occur secondary to disseminated infection, as 
typically seen with Fusarium species or Scedosporium prolificans. These cases are however more 
likely to present with ecthyma gangrenosum-like features than with NF, whereas Candida species and 
Cryptococcus neoformans tend to cause local nodular infection or cellulitis. Although primary 
cutaneous cryptococcosis has been described, disseminated cryptococcal disease especially to the 
central nervous system should be excluded. In a review of 12 patients with C. neoformans NF, the 
majority were immunosuppressed including 6 post-transplant patients. Despite combination treatment 
with surgical debridement and antifungal therapy with amphotericin B and 5-flucytosine induction 
therapy, overall mortality was 41.6% [50]. 
 
Cases of fungal NF of the head and neck due to Zygomycetes, in particular Apophysomyces species, 
have been reported in patients with decompensated diabetes, and results are often fatal [51]. A case 
series from Northern India identified seven cases (six due to A. variabilis and  one due to A. elegans) 
possibly linked to infections following intramuscular injections [52].  
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Moulds can cross tissue planes and are angio-invasive, causing thrombosis, secondary infarction and 
local or extensive necrotic infection. Infections due to zygomycete fungi (cutaneous mucormycosis) 
follow a more rapid course from localised infection or an eschar to life-threatening gangrene [53-55]. 
Dissemination can also occur. Diagnosis can be delayed due to difficulties in obtaining a 
microbiological identification, for example Mucor species are fastidious if specimens are poorly 
handled and diagnosis may depend on adequate histopathology and the detection of irregular aseptate 
hyphae. Treatment requires early and repeated surgical debridement combined with medical therapy 
including a broad spectrum antifungal such as liposomal amphotericin B (or isavuconazole if 
zygomycetes are suspected). Compared with Aspergillus species infections medical treatment options 
in Mucor species infections are limited and the clinical response is less predictable [56]. 
 
 
 
6. Necrotising skin infections in the immunocompromised  
Immunosuppressed patients appear to be more susceptible to NSSTI, primarily related to the increased 
risk of translocation of bowel organisms, and the degree and duration of the neutropenia as well as 
frequent presence of mucositis related to chemotherapeutic agents or graft versus host disease [57]. 
In the immunocompromised host, physical examination and clinical findings may be subtle hence the 
diagnosis can be even more challenging and laboratory findings can be nonspecific. Often the 
diagnosis is only considered late in the course of the disease when tissue necrosis is obvious and the 
patient is critically ill. Unsurprisingly, these patients tend to have poor prognosis and unfavourable 
outcomes. 
In a retrospective study of 668 NF cases using the National Surgical Quality Improvement Program 
registry, conditions associated with immunocompromised status such as malignancy and treatment 
with corticosteroids were reported in less than 10% of cases and were found to be associated with 
increased mortality. No data was reported in this study on the characteristics of NF presentation in 
immunocompromised patients [58].  
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In another retrospective study involving 201 patients from a single centre the authors tried to identify 
the characteristics of NF presentation in immunocompromised patients. Immunocompromised patients 
reported less purulent drainage, lower systolic blood pressure and were more frequently admitted to 
medical units( even after referrals to tertiary centers) and were less likely to undergo surgical 
debridement at the time of admission resulting in poorer outcomes. Laboratory findings highlighted an 
important difference in the white blood cell count, which was lower than in the general population. 
This should be considered when calculating the LRINEC score in the immunocompromised.  
Immunocompromised patients had 2 times higher mortality (~ 40%) than NF-related mortality in 
immunocompetent individuals. There was no difference in microbiological findings or antimicrobial 
therapy highlighted in immunocompromised patients [59].  
Ecthyma gangrenosum, haemorrhagic pustules that evolve into necrotic ulcers, is a relatively 
uncommon condition, but is one of the commonest manifestations of necrotising skin infections in 
immunosuppressed patients [60]. At one time it was postulated that this condition was pathognomonic 
of Pseudomonas aeruginosa bacteraemia. It is now clear that a variety of bacteria as well as fungi 
including Candida spp, Fusarium and Aspergillus can also cause ecthyma gangrenosum. The 
pathophysiology is that the organisms invade the venules, resulting in secondary thrombosis of the 
arterioles, tissue oedema, and necrosis. Many patients with ecthyma gangrenosum have an associated 
bacteraemia. Blood cultures and skin biopsies are necessary for diagnosis. The differential diagnosis 
of ecthyma gangrenosum and NSSTI in immunosuppressed patients includes any process that can 
produce skin necrosis including acute graft versus host disease, drug-induced skin necrosis, 
calciphylaxis, septic emboli, diabetic microangiopathy, disseminated intravascular coagulation, 
vasculitis, and Sweet‘s syndrome [61]. Skin biopsies should be sent for tissue culture for bacteria, 
fungi, yeasts, and mycobacteria. In addition to urgent surgical debridement, treatment entails empiric 
coverage for P. aeruginosa, enteric Gram negative bacteria, staphylococci and fungi until culture 
results are available.  
Diagnosis of NF and/or myonecrosis should be considered in any immunocompromised patient with 
fever, tachycardia, and localized pain out of proportion to the physical findings. The spectrum of 
potential pathogens is expanded to include rare invasive moulds, fungi, mycobacteria and even 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
parasites in certain geographical regions. Existing anti-infective prophylaxis may select for multidrug 
resistant organisms or azole resistant moulds and fungi. The need for multiple invasive procedures and 
devices increases the risk of environmental introduction. Where possible, immunosuppressive 
regimens should be tapered. Data on the optimal management of these patients remains limited and 
should be individualised.  
 
7. Necrotising infections in intravenous drug users:  
SSTIs are much more common in intravenous drug users (IVDUs) than the general population, 
reasons include that over half of IVDUs are colonised with S.aureus; they sustain repeated non-sterile 
injections; and may have relative immunodeficiency due to poor nutrition and/or HIV infection. 
Observational studies among IVDU populations report SSTIs occurring in 30-60% at any time and at 
least yearly in 10%-34% of IVDUs [62-64]. In a case-controlled study including 151 IVDUs, risk 
factors for skin and soft-tissue abscesses (SSTA) included direct injection into skin or muscle [65]. 
Other risks include non-vein injection (―skin-popping‖ – injecting subcutaneously and ―muscle-
popping‖ – intramuscular injection) and injecting into the neck or groin 63]. In addition, the particular 
drug being injected influences the risk of infection, with ―speed-ball‖, ―black tar heroin‖ and 
prescribed opiates all being associated with a higher risk of infection. 
Although most invasive infections in IVDU are due to S. aureus including CA-MRSA [66], the range 
of causative organisms is much broader than in the general population. In addition to Gram positive 
cocci, SSTI in IVDUs due to Candida species, Bacillus anthracis, anaerobes (including Clostridium 
species) and environmental bacteria such as Pseudomonas species are well described. Hence it is 
imperative for diagnostic samples to be taken, ideally prior to empiric antibiotic treatment, including 
pus from abscesses or furuncles, and blood cultures in those with systemic symptoms.  
The clinical presentation of SSTIs in IVDUs differs from that of the general population, with IVDUs 
more likely to have multiple abscesses, involvement of the upper limb and groin, and to require 
surgical drainage in the operating theatre. The most common SSTI in IVDUs are skin abscesses, 
usually at injection sites, most commonly in the cubital fossa, the groin and the neck. Cellulitis, NF 
and furunculosis also occur but are less common. Imaging is often needed to differentiate SSTA from 
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other lesions (e.g., haematomas, phlegmon or vascular complications) and evaluate the extent of 
infection [66]. 
If the presence of an abscess is confirmed, complete incision and drainage should be performed. 
Uncomplicated SSTI such as cellulitis can be treated with antimicrobials active against Gram-positive 
bacteria (Table 1) However, SSTA are polymicrobial in up to 50% of cases and can include B. 
anthracis and anaerobes due to drug contamination or heat-resistant anaerobes [65 66, 67]. 
Furthermore, the presence of devitalised tissue at the injection site in heroin users represents an ideal 
anaerobic microenvironment for life threatening infections such as wound botulism, tetanus, and NF 
[65, 68-70]. Other complications of SSTI in IVDUs include pyomyositis, bacteraemia, and 
endocarditis as well as chronic cutaneous venous ulcers that are often debilitating and require a 
multidisciplinary approach involving vascular and plastic surgeons, and can potentially lead to 
osteomyelitis. Management plans should include management of comorbidities such as alcohol and 
drug dependence. Endocarditis needs to be excluded and the opportunity taken to offer counselling 
and to check patients for blood borne viruses.  
 
8. Paediatric necrotising SSTI  
NSSTI is an uncommon, but potentially devastating infection in childhood responsible for 1.12/10,000 
hospital discharges [71]. An association of NSSTI with several comorbid conditions including 
coagulopathy, diabetes mellitus, electrolyte disturbance, and obesity has been documented. Cases 
associated with varicella are reported less frequently after varicella vaccination. 
Microbiological investigation from non-haematogenous sites demonstrates that streptococci and 
staphylococci are reported with the highest frequency and that Gram-negative organisms are cultured 
in less than 10% of cases. Staphylococci are the main bacteria isolated from blood cultures. 
Polymicrobial infections exceed 10% and P. aeruginosa infections are reported in the 
immunocompromised. Children with NSSTI are frequently febrile and report local symptoms and 
pain, and severe cases present with tachycardia, hypotension and altered mental status. The legs and 
trunk are the sites affected most frequently. Cumulative rates of ICU admission approaches 20%, but 
children aged 4 years or less report a rate of ICU admission exceeding 60% according to a 
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retrospective study by Endorf et al. On the basis of this study surgery involving the skin or muscle was 
performed in the majority of cases however the need for a fasciotomy was less than 10%. There was a 
link between surgery within 24 hours from admission and favourable outcomes [72]. 
Broad-spectrum antibiotics are frequently administered as empiric therapy, covering a range of 
pathogens including P. aeruginosa and MRSA in highly endemic areas. No class of antibiotic has 
been particularly associated with a favourable outcome. The mortality rate for NSSTI in children is 
estimated at 6%. The main variables affecting the mortality rate are severe sepsis and mechanical 
ventilation. Amputations are reported in 4% or less of the cases investigated. Children experiencing 
NSSTI had to be discharged more frequently to a rehabilitation nursing facility than the overall 
population of hospitalised children [73].  
 
9. Pyomyositis  
Pyomyositis is an acute bacterial infection of skeletal muscle that often arises from haematogenous 
spread and results in localized abscess formation. Pyomyositis is more frequent in tropical areas, for 
example, in eastern Uganda, 400-900 cases of tropical myositis occur per year while approximately 
676 cases have been reported in the US literature since 1971. The peak incidence of tropical 
pyomyositis is in children aged 2 to 5 and young adults aged 20 to 45, while the majority of temperate 
pyomyositis cases occur in adults. Males appear to be more commonly affected than females. Its 
incidence has increased in temperate zones, particularly among IVDUs, immunosuppressed patients 
such as those with HIV, patients with underlying comorbidities such as diabetes mellitus and cirrhosis 
and patients with  concurrent infections including toxocariasis and varicella. Traumatic injuries also 
increase the risk of pyomyositis since haematoma formation and increased muscle perfusion provide 
favourable bacterial growth conditions [74-78]. 
The microorganism most often responsible for pyomyositis is S. aureus, causing up to 90% of 
infections in tropical areas and 75% in temperate zones, followed by GAS. Less frequent agents 
include Streptococcus pneumoniae, Neisseria meningitidis and Gram negative bacilli. E. coli is an 
emerging agent of pyomyositis in patients with haematological malignancies. Rare cases of 
mycobacterial pyomyositis have also been reported. 
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Typically, patients with pyomyositis present with fever and muscle pain, most often localised to a 
single muscle group affecting the lower limbs or psoas muscles, but any muscle group can be affected 
including pelvic and upper extremity muscles and multifocal infection has been observed in up to 20% 
of cases. Three clinical stages are commonly described (Table 3) [42, 76] 
MRI is the most useful imaging modality for the diagnosis of pyomyositis, showing signs of muscle 
inflammation. CT scan and ultrasonography may be helpful [42, 79, 80]. Drainage may be guided by 
imaging and the culture of specimens is crucial for microbiological diagnosis and to obtain antibiotic 
susceptibility data. Blood cultures are positive in 10-35% of cases. Leukocytosis, elevated ESR and 
CRP are common findings but there are no specific biological markers of pyomyositis.  Mortality is 
reported in approximately 10% of patients. 
 
 
 
10. Gas gangrene  
 
Gas gangrene or clostridial myonecrosis is caused by an anaerobic, Gram-positive, spore-forming 
bacillus of the genus Clostridium and C. perfringens is the most common species. Other aerobic and 
anaerobic bacteria are also capable of forming gas and can cause non-clostridial gas gangrene. C. 
perfringens produces at least 20 exotoxins including lethal Alpha and Beta toxins which can have 
necrotising and haemolytic effects. The true incidence is not known. Clinical presentation depends on 
precipitating factors e.g. trauma or surgery or spontaneous gas gangrene in patients with occult 
malignancies. 
 
Like other NF infections, sudden onset disproportionate pain is usually present and worsens as the 
underlying infection spreads with or without constitutional symptoms, hypotension and altered mental 
status. The pain is followed by localised swelling, discharge (non-odorous or a sweet odour) and 
progressive skin changes including a dark bluish discolouration with blisters and haemorrhagic bullae. 
Crepitus may not always be detected with palpation due to swelling and oedema.  
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Patients‘ WBC may be normal; however their biochemical profile may show significant metabolic 
abnormalities frequently associated with tissue injuries with hypotension and toxic shock. Presence or 
absence of gas in soft tissue on X-ray, neither confirms nor excludes the diagnosis of gas gangrene.  
CT, MRI and ultrasound imaging can all be used, but may not exclude a diagnosis and may cause 
delay in management. Early surgical exploration, biopsy and extensive debridement can confirm the 
diagnosis and can be a determining factor for successful outcomes with adjuvant therapies including 
antimicrobials (Table 1) and IVIG. The addition of clindamycin, chloramphenicol, rifampin or 
tetracycline may be effective by inhibiting the synthesis of clostridial exotoxins [81].
  
The mortality 
rate is very high, varying from 25% to 100% in individuals with spontaneous gas gangrene and in 
cases where surgical debridement is delayed [82,83].
 
 
 
11. The role of Intravenous immunoglobulin (IVIG) 
 
IVIG is prepared from pooled immunoglobulin from a large number of human donors. The continuing 
increase in demand has led to concerns over availability and rising costs. It is generally well tolerated 
although anaphylactoid reactions can occur and there are ongoing fears about the risk of transmission 
of infections such as CJD [84]. 
With regards to its place as adjunctive therapy in the management of NSSTI, experimental studies 
have shown that IVIG results in the neutralisation of superantigens produced by GAS and S. aureus, 
immunomodulation of the inflammatory cascade and may assist bacterial opsonisation [85-88]. There 
are only a few large randomised controlled trials supporting the use of IVIG in NSSTI and 
publications are largely limited to numerous case reports, small comparative observational studies and 
retrospective reviews [89-91].  Its use was evaluated in a multicentre, randomised double-blind 
placebo-controlled study which was terminated prematurely due to slow patient recruitment. Results 
from 21 enrolled patients showed a significant decrease in the sepsis-related organ failure assessment 
score and, although statistical significance was not reached, a 3.6 times higher mortality rate was seen 
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in the placebo group [92]. Furthermore an observational cohort study involving 21 patients given 
adjunctive IVIG therapy for streptococcal toxic shock syndrome and 32 control patients reported 
significantly reduced mortality rates in patients given IVIG compared with controls (67% vs. 34%) 
[93]. A Swedish comparative observational study involving 75 patients with streptococcal toxic shock 
syndrome where most patients had SSTI also revealed a significantly improved 28 day mortality rate 
in the patients who received IVIG (87% vs. 50%) [94]. These reports, together with those detailing the 
mechanistic action of IVIG, support the use of IVIG as an adjunctive treatment in severe NSSTI 
caused by GAS and S. aureus; however larger trials are needed to support its use given the shortage of 
IVIG and the associated cost. In contrast to these publications, a retrospective study involving a 
paediatric cohort showed no mortality benefit but higher associated costs in those patients given IVIG, 
again stressing the importance for further clinical trials to investigate this [95]. 
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Conclusions  
 
NSSTIs are the most severe form of SSTIs. The ICS working group felt it important to discuss these 
infections in this review because of two main factors. Firstly, these infections commonly afflict even 
previously healthy people in the community without warning, rapidly progressing to sepsis and death 
and those who survive may be left with devastating, life-changing disabilities. Secondly, clinicians 
may lack the experience to recognise NF early and although the majority of SSTIs do not result in 
rapid destruction of soft tissue and toxaemia, it is important for all health professionals to be aware of 
these infections and consider them when patients present with pain out of proportion to the clinical 
signs with systemic, flu like symptoms and feverishness with raised inflammatory markers. This 
manuscript highlights some of the challenges associated with clinical diagnosis, as well as areas for 
future study and research in the fields of antimicrobials and adjuvant therapy, emphasising the urgency 
of surgical referral and debridement in any suspected cases of NSSTI. As members of ISAC we would 
like to propose the formation of an International Registry for cases of NSSTI to learn more about 
diagnostic and therapeutic opportunities for these cases.  
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Figure 1:  Early recognition of necrotising soft tissue infection aid memoir  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2a. Rapid changes  in the abdominal wall with blistering and possible necrosis was noted  
 
The patient had a fall at home and was admitted to the emergency department (ED) with a bruised chest wall and possible rib 
fracture; she was discharged with analgesia. Four days later she was readmitted in a confused state and complaining of a 
Necrotic (or cellulitis area) 
Excruciating pain (disproportionate to skin changes) 
Crepitus (may not be always present) 
Fever (with or without raised inflammatory markers) 
Ascending (demarcate the area with date/time) 
Swelling  
Contact surgeons (urgently if any clinical suspicion, even if the above features not present) 
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headache. She had no significant past medical history apart from penicillin allergy and a significant alcohol intake of 100g 
(10 standard drinks)/ week. On examination there was extensive left chest and abdominal wall bruising, in keeping with the 
previous fall and local trauma. Diffuse erythema was also noted over the anterior abdominal wall and there was a slight 
break, but no discharge, in the skin at the site of presumed injury associated with the fall. A diagnosis of delayed splenic 
rupture was suggested and she had an abdominal ultrasound, which showed no abdominal free fluid or gas and a possible 
small haematoma in the abdominal wall. A surgical consultation recorded that there were no surgical concerns.  
Investigations were as follows: Hb 109 gm/L, WBC 11.9, platelets 120, CRP 87 with normal renal and liver function. An 
infectious diseases opinion was sought. The mild erythema was felt to be early cellulitis and empirical treatment with IV 
clindamycin 600mg qds was commenced.  
Two hours later the patient became more confused, acidotic and the CRP increased to 240 and WBC to 18.9. She was 
transferred to intensive care (ICU) where rapid changes in the abdominal wall with blistering and possible necrosis was noted 
as demonstrated in the picture. 
 
Figure 2b. After debridement. 
 
A further ultrasound showed an abdominal wall fluid collection and an urgent CT scan showed 
extensive subcutaneous oedema at the left flank overlying the left ribs. Her blood pressure was 80/45 mmHg and she required 
cardiovascular support with dobutamine and noradrenaline. She underwent surgical debridement as demonstrated. A Gram 
stain of the debrided tissue showed short chains of Gram positive cocci, and subsequent culture grew GAS. She was treated 
empirically with meropenem and linezolid and received two doses of IVIG at doses of 2gm/kg. The patient had three further 
surgical debridement and remained in the ICU for two months.    
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Table 1: Antibiotic treatment of necrotising fasciitis 
Type of necrotising fasciitis Antibiotic treatment 
Unknown etiology (empirical*)  or 
Polymicrobial (aerobic and anaerobic 
pathogens) 
Beta lactams (Piperacillin/Tazobactam or Cabapenem or  Cephalosporins) plus 
Clindamycin  
In true Beta lactam allergic patients substitute the beta lactam with a fluoroquinolone 
Suspicion or confirmed MRSA Add: Vancomycin or Daptomicin or Linezolid or other new alternatives e.g. Tedizolid, 
Dalbavancin, Ceftaroline, Tigecycline  
Targeted treatment for streptococcal or 
clostridial infections  
[Benzylpenicillin or Amoxicillin] + Clindamycin  
(Metronidazole for clostridial infections) 
 
*NF is a surgical emergency and urgent referral to surgeons is a priority.  
Abscesses need to be drained (in IVDUs) 
Imaging is important, but normal imaging does not exclude the diagnosis of NF 
Always follow local epidemiology and guidance. The optimal duration of antibiotic treatment has not been defined. 
Antibiotics should be continued until surgical treatment is completed (no additional debridement is needed), the patient has 
improved clinically and fever has resolved for 48-72 hours. 
 
 
Table2: Summary salient clinical data from the largest reported case series and literature reviews on other Gram negative 
bacterial NF. 
Pathogen Number  of 
cases 
Age (years) Male Predisposing 
conditions 
Surgery 
performed 
No of 
Death 
(%) 
Refernce 
Escherichia coli 7 52-91 5 (71%) Cancer 3 (43%), 
liver disorder 1 
(14%) 
2 (29%) 7 (100%) 32 
Klebsiella spp. 17 1-76 13 (76%) Diabetes 12 
(71%), liver 
disorder 4 (24%), 
cancer 2 (12%) 
13 (76%) 5 (29%) 33 
Pseudomonas spp. 37 2 months-85 15 (41%) Cancer 20 
(54%), diabetes 1 
(3%) 
16 (43%) 9 (24%) 34 
Salmonella spp. 6 2 months-76 2 (33%) Corticosteroid 4 
(67%) 
6 (100%) 1 (17%) 35 
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Aeromonas spp. 13 41-81 11 (85%) Cancer 5 (38%), 
diabetes 3 (23%), 
liver disorder 3 
(23%) 
8 (62%) 9 (69%) 36 
Vibrio 
parahaemolyticus 
8 40-92 7 (88%) Diabetes 4 
(50%), liver 
disorder 3 (38%) 
6 (75%) 3 (38%) 37 
 
 
Table 3: Clinical stages of pyomyositis and management summary  
 
Stage  Description  Management summary  
Stage 1 or 
invasive stage 
Around 2% of patients present in this stage. This stage lasts from 10 
to 21 days. There is an insidious onset of dull, cramping pain, low-
grade fever, muscle ache, general malaise and anorexia. There is 
localized oedema, sometimes described as indurated or woody, with 
little or no tenderness. There is no abscess, and examination of 
aspiration specimens is unrevealing. 
 
Antibiotics tend to be sufficient (i.e. no drainage is needed). These must be 
active against S. aureus (including MRSA in highly endemic areas) and 
beta-haemolytic streptococci. Consequently, possible agents, for empiric 
use, are vancomycin, daptomycin, linezolid, ceftaroline and tigecycline. 
Due to its potency to inhibit the synthesis of bacterial toxins, clindamycin 
may be added to vancomycin or a Beta-lactam. Antimicrobial treatment 
must also cover Gram negative bacteria and anaerobes in 
immunocompromised hosts. That is why a beta-lactam such as ampicillin-
sulbactam, amoxicillin-clavulanate, or ticarcillin-clavulanate or piperacillin-
tazobactam must be combined with vancomycin or another agent active 
against MRSA. The recommended duration of antibiotic treatment is at least 
2-3 weeks. 
Stage 2 or 
purulent or 
suppurative 
stage 
 
About 90% of patients present in this stage. Mean duration of 
symptoms varies from 24 hours to 12 days. Fever and chills are 
usually present. This stage is characterized by abscess formation. 
Pathologic findings on biopsy show oedematous muscle fibers, 
lymphocytic infiltration, and suppuration as the muscle belly is 
replaced by pus. The involved muscle is usually tender and the 
overlying skin may be normal or mildly eruptive. 
 
 
In addition to antibiotics as above, early CT (or ultrasound)-guided 
percutaneous drainage should be performed in patients with stage 2 or 3 
pyomyositis. Surgical intervention may be required in case of unsatisfactory 
percutaneous drainage or muscle necrosis.  
 
Stage 3 or  
late stage  
High fever, severe pain, local signs of infection and systemic 
manifestations of sepsis may be present. The final stage is 
characterized by septicemia, metastatic abscesses, and multi-organ 
dysfunction which is associated with high mortality. There is 
exquisite tenderness of the involved area. 
 
 
 
 
